Allergoid–mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring

Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyt...

Full description

Authors: Benito Villalvilla, Cristina; Pérez Diego, Mario; Angelina Querencias, Alba; Kisand, Kai; Rebane, Ana; Subiza, José Luis; Palomares Gracia, Óscar
Format: Article
Publication date:2022
Country:España
Institution:Universidad Complutense de Madrid (UCM)
Repository:Docta Complutense
Language:English
OAI Identifier:oai:docta.ucm.es:20.500.14352/71283
Online Access:https://hdl.handle.net/20.500.14352/71283
Access Level:Open access
Keyword:577.1
Allergen-specific immunotherapy
allergoid–mannan conjugates
monocytes
tolerogenic dendritic cells
regulatory T cells
metabolism
epigenetics
Química
Biología molecular (Química)
Bioquímica (Química)
23 Química
Summary:Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyte differentiation remains unknown.

Similar Items